The Silicon Valley standard agreement is: spend money now, predict a revolutionary future, and hope the market understands. By 2026, this agreement has forcefully entered a field that a decade ago was almost entirely academic: anti-aging. Billions of dollars have flowed into biotech companies promising to reverse aging. Here is the review of who is actually close to results, and who is still promising.
1. Altos Labs - The Giant No One Has Seen Results From
Funding: $3 billion in a single round. Investors: Jeff Bezos, Yuri Milner, and secret offices from Saudi Arabia. Founders: Almost every major legend of aging research, including Juan Carlos Izpisua Belmonte, Manuel Serrano, and others. The company hired Rick Klausner from NCI as CEO.
Product: Partial reprogramming. Introducing Yamanaka factors into old cells to return them to a young state, without turning them into stem cells (and thus without losing their identity). This technology has been praised since 2016 when it was published. But since Altos was founded in 2022, we are in 2026 and still haven't seen clinical results.
Status: Not yet in human studies. Most results are still in isolated organs. The company spans three facilities (San Diego, Cambridge UK, San Francisco) with about 300 researchers. The market expects clinical trials to open towards 2027-2028.
2. Life Biosciences - The First Win
Funding: About $220 million by 2026. Founder-Chief Advisor: David Sinclair from Harvard. CEO: Jerry McLaughlin.
Product: ER-100, a gene therapy based on three Yamanaka factors (OCT4, SOX2, KLF4) delivered via AAV virus directly into the patient's eyes. This rejuvenates nerve cells in the visual organs.
Status: FDA approval for human trials in January 2026. This is the first-ever trial of partial reprogramming in humans. First patients: glaucoma and NAION (acute optic nerve injury) patients. The trial is Phase 1 (safety), with results expected by the end of 2026 or 2027.
Why this matters: While Altos tries to treat the whole body at once, Life starts step-by-step in a limited organ (the eye). This is a more cautious approach but also safer and with a higher chance of clinical success.
3. Retro Biosciences - The Aim for 10 Years
Funding: $2 billion. Investors: Sam Altman (OpenAI). Official goal: Add 10 years to human lifespan.
Product: Two parallel paths:
- Reprogramming of hematopoietic stem cells (blood-specific stem cells)
- RTR242: A pill that boosts autophagy (cellular cleaning). Now in human studies for Alzheimer's
Status: Early stage, but RTR242 is already in the clinic. Results expected in a year.
4. NewLimit - The Anti-Aging of the Immune System
Funding: $130 million in Series B round (2024). Founders: Brian Armstrong (CEO of Coinbase) and Blake Byers.
Product: Epigenetic reprogramming of T cells (part of the immune system). They aim to reverse immune system aging, not the whole body.
Status: All experiments in mice. Entry into the clinic expected in 2027.
5. Calico Labs - The Google Elephant
Funding: $2.5 billion from Google/Alphabet. Founded in 2013 by Larry Page.
Product: Unclear. The company is known to be very secretive. Three years ago, they revealed they are investing in research on naked mole rats (live 30 years!) and broad genetic studies.
Status: 12 years after founding, still no product in the clinic. The most stuck point in the field.
6. Rejuvenate Bio - Rejuvenating Pets
Funding: About $50 million. Founder: Noah Davidson, a Harvard researcher.
Product: An interesting approach. Starting with dogs. If the company can dramatically extend dog lifespans, it will be a proof of principle. They showed that with partial reprogramming, old mice improved all health metrics without side effects.
Status: Trials in dogs with heart problems. If successful, they will be the first to prove partial reprogramming in a large animal.
7. Shift Bioscience - The Epigenetic Clock for Treatment
British, raised about $26 million. First heard of in 2024 when they developed their own epigenetic clock and now use it to design molecules that turn the clock back.
8. Genflow Biosciences - SIRT6
British. Aims to license the SIRT6 gene as a drug. SIRT6 is a specific protein that is more active in super-centenarians (people who lived over 110 years). The company is trying to create a pharmaceutical version for the general population.
9. BioAge Labs - Drugs from Healthy People
Unique approach: Follow very healthy people over 80, identify blood components unique to them, and develop drugs that mimic these components.
10. Loyal - The First Pet Company with FDA
The first to receive FDA approval for a longevity drug, albeit for dogs. LOY-002 extends the lifespan of large dogs by about 12 months. This is proof that FDA approval for anti-aging drugs is possible.
11. Insilico Medicine - AI for Drug Design
Swedish with offices worldwide. Uses AI to design anti-aging drugs. Discovered INS018_055, a molecule that works against pulmonary fibrosis (a sign of aging), now in Phase 2.
Summary: Who is Actually Advancing in 2026?
The representative in the clinic: Life Biosciences. The one with the most money: Altos. The one with the most noise: Retro. The one with concrete results in large animals: Loyal. The one with the most innovative approach: NewLimit.
Realistic expectation: By 2030, we will see the first clinical trials conclude. By 2035, if all goes as planned, the first longevity drug could reach the clinic. Until then, these companies will be a melting pot of immense research.
What Does This Mean for You?
If you are 50 or older, these drugs are still far off. But if you are 30, there is a good chance that during your career there will be progress that significantly extends your life. Until then, the proven interventions remain the same: physical activity, nutrition, sleep, and social relationships.
💬 תגובות (0)
היו הראשונים להגיב על המאמר.